Samrat Pharmachem Hits New 52-Week Low at Rs. 271.1

Samrat Pharmachem, a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs. 271.1 today, marking a significant downturn in its stock performance. This decline comes after the stock opened with a loss of 2.11% and has been trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent downward trend.
Despite this, the stock managed to outperform its sector by 3.61% today, with an intraday high of Rs. 288, reflecting some volatility in trading. Over the past year, Samrat Pharmachem has experienced a notable decline of 33.86%, contrasting sharply with the Sensex, which has gained 5.35% during the same period.

The company's financial metrics reveal a challenging landscape, with a reported PAT of Rs. 2.15 crore reflecting a decrease of 43.57%. Additionally, the stock has consistently underperformed against benchmarks, generating negative returns over the last three years. As the market continues to evolve, the performance of Samrat Pharmachem remains a focal point for stakeholders in the pharmaceuticals sector.